Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

Jad Othman; Nicola Potter; Sylvie D. Freeman; Nicholas McCarthy; Jelena Jovanovic; Manohursingh Runglall; Joanna Canham; Ian Thomas; Sean Johnson; Amanda Gilkes; Jamie Cavenagh; Panagiotis Kottaridis; David Taussig; Claire Arnold; Claire Hemmaway; Dominic Culligan; Ulrik Malthe Overgaard; Mike Dennis; Alan K. Burnett; Nigel H. Russell; Richard Dillon

doi:10.1182/blood.2025029556

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

Jad Othman
, Nicola Potter
, Sylvie D. Freeman
, Nicholas McCarthy
, Jelena Jovanovic
, Manohursingh Runglall
, Joanna Canham
, Ian Thomas
, Sean Johnson
, Amanda Gilkes
, Jamie Cavenagh
, Panagiotis Kottaridis
, David Taussig
, Claire Arnold
, Claire Hemmaway
, Dominic Culligan
, Ulrik Malthe Overgaard
, Mike Dennis
, Alan K. Burnett
, Nigel H. Russell

Richard Dillon^*

^*Corresponding author for this work

Immunology and Immunotherapy

Research output: Contribution to journal › Letter › peer-review

3 Downloads (Pure)

Abstract

We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.

Original language	English
Pages (from-to)	1862-1867
Number of pages	6
Journal	Blood
Volume	146
Issue number	15
Early online date	6 Aug 2025
DOIs	https://doi.org/10.1182/blood.2025029556
Publication status	Published - 9 Oct 2025

Access to Document

10.1182/blood.2025029556Licence: None: All rights reserved

OthmanJ2025Induction
This research was originally published in Blood. © the American Society of Hematology.
Final published version, 1.77 MBLicence: Other (please specify with Rights Statement)

https://orca.cardiff.ac.uk/id/eprint/180430/

Cite this

Othman, J., Potter, N., Freeman, S. D., McCarthy, N., Jovanovic, J., Runglall, M., Canham, J., Thomas, I., Johnson, S., Gilkes, A., Cavenagh, J., Kottaridis, P., Taussig, D., Arnold, C., Hemmaway, C., Culligan, D., Overgaard, U. M., Dennis, M., Burnett, A. K., ... Dillon, R. (2025). Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. Blood, 146(15), 1862-1867. https://doi.org/10.1182/blood.2025029556

@article{774a3631a1284a7699bba34f7023ee45,

title = "Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML",

abstract = "We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.",

author = "Jad Othman and Nicola Potter and Freeman, \{Sylvie D.\} and Nicholas McCarthy and Jelena Jovanovic and Manohursingh Runglall and Joanna Canham and Ian Thomas and Sean Johnson and Amanda Gilkes and Jamie Cavenagh and Panagiotis Kottaridis and David Taussig and Claire Arnold and Claire Hemmaway and Dominic Culligan and Overgaard, \{Ulrik Malthe\} and Mike Dennis and Burnett, \{Alan K.\} and Russell, \{Nigel H.\} and Richard Dillon",

year = "2025",

month = oct,

day = "9",

doi = "10.1182/blood.2025029556",

language = "English",

volume = "146",

pages = "1862--1867",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "15",

}

Othman, J, Potter, N, Freeman, SD, McCarthy, N, Jovanovic, J, Runglall, M, Canham, J, Thomas, I, Johnson, S, Gilkes, A, Cavenagh, J, Kottaridis, P, Taussig, D, Arnold, C, Hemmaway, C, Culligan, D, Overgaard, UM, Dennis, M, Burnett, AK, Russell, NH & Dillon, R 2025, 'Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML', Blood, vol. 146, no. 15, pp. 1862-1867. https://doi.org/10.1182/blood.2025029556

TY - JOUR

T1 - Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

AU - Othman, Jad

AU - Potter, Nicola

AU - Freeman, Sylvie D.

AU - McCarthy, Nicholas

AU - Jovanovic, Jelena

AU - Runglall, Manohursingh

AU - Canham, Joanna

AU - Thomas, Ian

AU - Johnson, Sean

AU - Gilkes, Amanda

AU - Cavenagh, Jamie

AU - Kottaridis, Panagiotis

AU - Taussig, David

AU - Arnold, Claire

AU - Hemmaway, Claire

AU - Culligan, Dominic

AU - Overgaard, Ulrik Malthe

AU - Dennis, Mike

AU - Burnett, Alan K.

AU - Russell, Nigel H.

AU - Dillon, Richard

PY - 2025/10/9

Y1 - 2025/10/9

N2 - We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.

AB - We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.

U2 - 10.1182/blood.2025029556

DO - 10.1182/blood.2025029556

M3 - Letter

SN - 0006-4971

VL - 146

SP - 1862

EP - 1867

JO - Blood

JF - Blood

IS - 15

ER -

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML

Abstract

Access to Document

Fingerprint

Cite this